Treatment of renal cell carcinoma: Current status and future directions

Answer questions and earn CME/CNE Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned from a nonspecific immune approach (in the cytokine era), to targeted therapy against vascular endothelial growth factor (VEGF), and now to novel immunotherapy agents. Multiple...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	CA: a cancer journal for clinicians 2017-11, Vol.67 (6), p.507-524
Hauptverfasser:	Barata, Pedro C., Rini, Brian I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Axl protein Biomarkers Biomarkers, Tumor - analysis Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - immunology Carcinoma, Renal Cell - pathology clinical trials Disease Management Forecasting Humans Immune checkpoint inhibitors Immunotherapy Immunotherapy - trends Kidney cancer Kidney Neoplasms - drug therapy Kidney Neoplasms - immunology Kidney Neoplasms - pathology Medical treatment Metastases Neoplasm Metastasis Oncology Patient Selection Platelet-derived growth factor programmed death 1 (PD‐1) Protein kinase Rapamycin Renal cell carcinoma targeted agents TOR protein Tyrosine Vascular endothelial growth factor vascular endothelial growth factor (VEGF)
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!